WOCKPHARMA Stock Overview
Wockhardt Limited, a pharmaceutical and biotech company, manufactures and markets pharmaceuticals, medicinal, and chemical products in India, the United States, the United Kingdom, Switzerland, Ireland, Mexico, Russia, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Wockhardt Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹582.85 |
| 52 Week High | ₹630.00 |
| 52 Week Low | ₹165.00 |
| Beta | 1.62 |
| 1 Month Change | 6.72% |
| 3 Month Change | 29.87% |
| 1 Year Change | 240.45% |
| 3 Year Change | 15.63% |
| 5 Year Change | 36.20% |
| Change since IPO | 116.02% |
Recent News & Updates
Recent updates
Subdued Growth No Barrier To Wockhardt Limited (NSE:WOCKPHARMA) With Shares Advancing 29%
Feb 21
There's Reason For Concern Over Wockhardt Limited's (NSE:WOCKPHARMA) Massive 28% Price Jump
Dec 19There's No Escaping Wockhardt Limited's (NSE:WOCKPHARMA) Muted Revenues
Oct 14Is Wockhardt (NSE:WOCKPHARMA) Using Too Much Debt?
Jun 23Estimating The Intrinsic Value Of Wockhardt Limited (NSE:WOCKPHARMA)
Feb 18Wockhardt (NSE:WOCKPHARMA) Is Making Moderate Use Of Debt
Jan 04Shareholders Will Probably Hold Off On Increasing Wockhardt Limited's (NSE:WOCKPHARMA) CEO Compensation For The Time Being
Jul 26Calculating The Intrinsic Value Of Wockhardt Limited (NSE:WOCKPHARMA)
May 18Calculating The Fair Value Of Wockhardt Limited (NSE:WOCKPHARMA)
Jan 26
What Did Wockhardt's (NSE:WOCKPHARMA) CEO Take Home Last Year?
Dec 01Shareholder Returns
| WOCKPHARMA | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 4.9% | -2.5% | -2.5% |
| 1Y | 240.4% | 55.2% | 44.5% |
Return vs Industry: WOCKPHARMA exceeded the Indian Pharmaceuticals industry which returned 55.2% over the past year.
Return vs Market: WOCKPHARMA exceeded the Indian Market which returned 44.5% over the past year.
Price Volatility
| WOCKPHARMA volatility | |
|---|---|
| WOCKPHARMA Average Weekly Movement | 8.1% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.3% |
Stable Share Price: WOCKPHARMA's share price has been volatile over the past 3 months.
Volatility Over Time: WOCKPHARMA's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1967 | 2,740 | Murtaza Khorakiwala | www.wockhardt.com |
Wockhardt Limited, a pharmaceutical and biotech company, manufactures and markets pharmaceuticals, medicinal, and chemical products in India, the United States, the United Kingdom, Switzerland, Ireland, Mexico, Russia, and internationally. It develops various molecules primarily in the areas of infectious diseases, such as WCK 5222, WCK 4282, WCK 4873, WCK 771 and WCK 2349, and WCK 6777 molecules; and active pharmaceutical ingredients. The company’s biopharmaceutical products include Glaritus, a long-acting biosimilar glargine; Wosulin, a recombinant human insulin; Wepox, an r-DNA erythropoietin; human insulin; and Biovac-B, a hepatitis B vaccine.
Wockhardt Limited Fundamentals Summary
| WOCKPHARMA fundamental statistics | |
|---|---|
| Market cap | ₹87.89b |
| Earnings (TTM) | -₹5.01b |
| Revenue (TTM) | ₹27.76b |
3.2x
P/S Ratio-17.8x
P/E RatioIs WOCKPHARMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WOCKPHARMA income statement (TTM) | |
|---|---|
| Revenue | ₹27.76b |
| Cost of Revenue | ₹12.38b |
| Gross Profit | ₹15.38b |
| Other Expenses | ₹20.39b |
| Earnings | -₹5.01b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -32.66 |
| Gross Margin | 55.40% |
| Net Profit Margin | -18.05% |
| Debt/Equity Ratio | 66.3% |
How did WOCKPHARMA perform over the long term?
See historical performance and comparison